咨询热线:400-1792-998
当前位置:主页 > 新闻动态 > 公司新闻公司新闻

【重磅新闻】强强联合!嘉检医学与华大智造在遗传病领域达成战略合作

发布时间 :2019-11-01 08:46 阅读 :


嘉检医学与
华大智造

在遗传病领域达成战略合作

AmCare Genomics Lab and MGI

 

 

reached strategic cooperation in genetic diseases

 

近日,深圳华大智造科技有限公司与广州嘉检医学检测有限公司在单基因遗传病基因检测临床应用方向达成战略合作协议。嘉检医学将基于华大智造高通量测序平台开发单基因遗传病基因检测的全流程整体解决方案,以实现遗传病基因检测从样本到报告解读的本地化,自动化和智能化。
 

Recently, Shenzhen MGI Technology Co., Ltd. and AmCare Genomics Lab reached a strategic cooperation agreement in the clinical application direction of single gene genetic disease detection. Based on MGI's high-throughput sequencing platform, AmCare Genomics Lab will develop a whole-process solution for genetic diseases detection of single-gene genetic diseases to realize the localization, automation and intelligence of genetic disease detection from sample to report interpretation.

 

华大智造总裁余德健表示:“嘉检医学对遗传病诊断需求有着十分丰富和深入的经验。此次与嘉检医学达成的战略合作,将进一步扩大华大智造测序技术在遗传病领域的应用。华大智造致力于打造开放式的基因测序平台,为用户提供更强大的生产工具,愿携手业内合作伙伴,共同促进中国高通量测序行业蓬勃发展。”

 

Duncan Yu, president of MGI, said: “AmCare Genomics Lab has rich and in-depth experience in the diagnosis of genetic diseases. The strategic cooperation withAmCare Genomics Lab will further expand the application of MGI's sequencing technology in the field of genetic diseases. MGI is committed to creating an open genetic sequencing platform to provide users with more powerful production tools. We are willing to work with industry partners to jointly promote the high-throughput sequencing industry in China."

 

嘉检医学张巍总经理表示,“华大智造的测序平台在遗传病检测应用上有着明显的优势,嘉检医学希望通过本次战略合作,将嘉检在遗传病检测和遗传咨询方面的经验与华大智造技术平台优势相结合,开发出更能满足医生和患者需求的遗传病检测产品。

 

The CEO of AmCare Genomics Lab, Professor Zhang Wei said, “The sequencing platform created by MGI has obvious advantages in the application of genetic disease detection. Through this strategic cooperation, AmCare Genomics Lab hopes to combine the experience of genetic disease detection and genetic counseling and the advantages of MGI's technology platform to develop genetic disease detection products that can meet the needs of doctors and patients better.

 

 

嘉检医学是中国首家拥有国际临床遗传三大专科资质认证(ABMG)的第三方临床基因检测服务机构。华大智造携手嘉检医学,也标志着其DNBSEQTM测序平台的生态合作伙伴,快速拓展至新兴的遗传病领域。据了解,遗传病涉及的病种繁多,需要检测的基因区域广,对测序平台的数据生产能力和质量有更高要求,华大智造的全面型高通量测序仪MGISEQ-2000【1】和超高通量测序仪DNBSEQ-T7等平台均能高效支撑此类大数据量检测的应用需求。双方的战略合作,将推动我国出生缺陷率防控和国内临床遗传专科的建立,实现该领域的“国产化、本地化、专业化”,为更多病人提供优质、便捷的专业化服务。

 

AmCare Genomics Lab is the first third-party clinical genetic testing service organization in China with three accredited international clinical genetic qualifications. MGI and AmCare Genomics Lab also mark the ecological partner of its DNBSEQTM sequencing platform. Rapid expansion to the emerging field of genetic diseases. It is understood that genetic diseases involve a wide variety of diseases, a wide range of genes to be detected, and higher requirements on the data production capacity and quality of sequencing platforms. The comprehensive Qualcomm created by MGI, the mass spectrometers DNBSEQ-G400 [1] and ultra-high-throughput sequencer DNBSEQ-T7 can effectively support the application requirements of such large data volume detection. The strategic cooperation between the two parties will promote the prevention and control of birth defects in China. The establishment of clinical genetics specialists to achieve "localization, specialization" in this field to provide quality and convenient professional services for more patients.

 

【1】MGISEQ-2000已在部分海外国家更名为DNBSEQ-G400
 
[1]Remark: DNBSEQ-G400 remain the original product name as MGISEQ-2000 in China and some other overseas countries.